Amgen AMGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Amgen Shares Still Look Undervalued

      Headlines

      Wed, 22 Apr 2015

      Amgen AMGN reported strong first-quarter results ..... negative moat trend as its pipeline advances. Amgen is entering a period of heavy launches ..... patients who will be eligible for therapy. Amgen 's revenue grew 11% to $5 billion in

    2. Amgen Outperforms in 1Q, Raises Guidance; Maintaining Our Fair Value Estimate

      Commentary

      Wed, 22 Apr 2015

      Amgen reported strong first-quarter results and ..... negative moat trend as its pipeline advances. Amgen is entering a period of heavy launches ..... patients who will be eligible for therapy. Amgen 's revenue grew 11% to $5 billion in the

    3. UPDATE 2- Amgen earnings boosted by higher drug prices, lower R&D

      Headlines

      Tue, 21 Apr 2015

      April 21 (Reuters) - Amgen Inc reported higher first-quarter earnings on Tuesday, helped by price increases for its best-selling drugs, as well as lower spending on research and development.

    4. Amgen 1st-quarter profit boosted by drug price rises, lower R&D

      Headlines

      Tue, 21 Apr 2015

      April 21 (Reuters) - Amgen Inc reported higher first-quarter earnings on Tuesday, driven by price increases for its biggest-selling drugs, as well as lower spending on research and development.

    5. A Push-Me, Pull-You Market

      Headlines

      Thu, 16 Apr 2015

      biotech of this size. Maxy-G34 is already in Phase II trials, and we think it still has a 30% chance of making it to the market, where it could compete with the likes of Amgen AMGN as a treatment for chemotherapy-induced neutropenia.

    6. UPDATE 1-U.S. FDA approves Amgen's Corlanor heart failure drug

      Headlines

      Wed, 15 Apr 2015

      April 15 (Reuters) - U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first...

    7. U.S. FDA approves Amgen heart failure drug

      Headlines

      Wed, 15 Apr 2015

      April 15 (Reuters) - U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first...

    8. Amgen to appeal rejection of bid to block Novartis biosimilar drug

      Headlines

      Wed, 25 Mar 2015

      SAN FRANCISCO, March 25 (Reuters) - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG's biosimilar form of Neupogen, Amgen 's blockbuster drug used to prevent infections...

    9. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      biosimilars (through a partnership with Amgen AMGN ) remain attractive internally developed ..... Thanks to its partnership with Amgen , we think Actavis possesses strong ..... term.) Under its partnership with Amgen , Actavis has biosimilar versions

    10. UPDATE 2-U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen

      Headlines

      Thu, 19 Mar 2015

      NEW YORK, March 19 (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen 's blockbuster drug used to prevent infections in cancer patients.

    « Prev12345Next »
    Content Partners